PHASE II STUDY OF DURVALUMAB (ANTI-PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome

INTRODUCTION

Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies.

AREAS COVERED

We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response.

EXPERT OPINION

We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.